Loading AI feed…

VVOS

Rating neutralAI MemoPost-earnings T+1

Vivos Therapeutics

As of 2026-08-18/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 revenue growth and margin improvement confirmed • 2026-08-18

Base target: $0 / p=45% prob

Biggest risk

The company remains cash constrained, loss-making, and dependent on additional financing. The 10-Q explicitly raises substantial doubt about going-concern status without new funding and highlights equity issuance, Nasdaq compliance, execution risk, and delayed Rebis expectations [#SEC-10Q-2026-08-14].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Q2 revenue rose about 35% year over year, gross profit and gross margin improved, and service revenue associated with the provider-focused model increased. If SCN-led patient volume continues scaling, the company could improve operating leverage [#SEC-10Q-2026-08-14].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-18

Base target

p=45%

Bull target

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Liquidity and dilution remain the immediate stock variable
SCN model must convert patient volume into cash-flow-positive scale
Q2 revenue rose about 35% year over year, gross profit and gross margin improved, and service revenue associated with the provider-focused model increased.

BearKey bullets

Going-concern warning and insufficient cash runway without additional financing.
Persistent operating losses, cash burn, debt obligations, and limited analyst coverage.
Potential equity issuance, dilution, and continued Nasdaq-compliance pressure.

WatchKey bullets

Q2 revenue growth and margin improvement confirmed

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $0 (p=45%)

Target spread vs base: +67% / -67%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=45%)Bear Target: $0 (p=35%)

Commentary

Headline flow is sparse and social coverage is absent. The post-print price reaction, consensus surprise, analyst revisions, and target changes are unavailable. Q2 operating results were constructive, but the going-concern warning and equity-financing dependence keep sentiment fragile and support a monitoring stance.

As of 2026-08-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Liquidity and dilution remain the immediate stock variable
SCN model must convert patient volume into cash-flow-positive scale

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=45% prob

Bear Target (Scenario probability)

$0 / p=35% prob

Analysis 2026-08-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-18
Q2 revenue growth and margin improvement confirmed
The June-quarter 10-Q reported $5.153 million of revenue versus $3.820 million year over year, gross profit of approximately $3.0 million, gross margin of 57% versus 55%, and a slightly improved operating loss. The earnings transcript confirms management reviewed Q2 results and 2026 plans, but consensus surprise and guidance revisions are unavailable [#SEC-10Q-2026-08-14] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 100.00% • Move 18.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Liquidity and dilution remain the immediate stock variable
2026-09-30
The 10-Q reported approximately $1.8 million of cash at June 30, 2026, stated that this would not fund operations and strategic objectives for the next twelve months, and disclosed substantial going-concern doubt without additional financing. Management expects financing to rely primarily on equity issuance, creating dilution and Nasdaq-compliance risk [#SEC-10Q-2026-08-14].
Prob 85% • Move -30% • Priced-in 65%

Long-term Catalysts

Months to a year

SCN model must convert patient volume into cash-flow-positive scale
2026-12-31
The filing says the SCN acquisition increased patient volume, top-line revenue, and lowered customer-acquisition costs, but revenues remain insufficient to cover expenses. The medical-provider model is new and unproven, while Rebis Health delays have reduced revenue expectations; durable upside requires sustained service growth, margin improvement, and financing without another capital reset [#SEC-10Q-2026-08-14].
Prob 30% • Move 70% • Priced-in 20%

Risks

Going-concern warning and insufficient cash runway without additional financing.
Persistent operating losses, cash burn, debt obligations, and limited analyst coverage.
Potential equity issuance, dilution, and continued Nasdaq-compliance pressure.
Rebis Health delays have led management to lower revenue expectations under the strategic alliance.
SCN and the medical-provider-focused model may not achieve sufficient patient volume or cash-flow leverage.

Peers

Symbol	Summary
BJDX	Same-sector micro-cap candidate; useful mainly as a funding and liquidity reference, not a direct obstructive-sleep-apnea treatment comp.
FEED	Same-sector micro-cap candidate with loose device and healthcare overlap; not a close product or revenue-model comparison.
MEDS	Same-sector micro-cap candidate best used for micro-cap financing and commercialization-risk framing rather than direct operating benchmarking.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-18

AI Stock Memo: VVOS - Vivos Therapeutics - RankAlpha